Background: Cisplatin based chemoradiotherapy (cis-RT) is the standard treatment in locally advanced cervical cancer (CC). Carboplatin chemoradiotherapy (carbo-RT) has not been validated in prospective phase III studies, although it is used in the presence of renal impairment, advanced age or comorbidities. Methods: Retrospective analysis of patients (pts) with CC stage IIB-IVA consecutively treated at Instituto do Cancer do Estado de Sao Paulo from May/2008 to December/2012. Primary endpoint was PSF and secondary OS and ORR (CR + PR). Survival was assessed by Kaplan-Meier curves, compared by the log-rank test, frequencies were compared by chi-square test Results: We analyzed 184 pts, 159 treated with cis-Rt and 25 carbo-RT. All received whole pelvic region external-been RT (45Gy and boost-12-14Gy- followed by brachytherapy-4x700cGy). Chemo was weekly cis (40mg/m2) or carbo (AUC2). Median age was 50.42 (21-80) in cis-RT and 64.18y (42-83) in carbo-RT. Most pts have squamous cell carcinoma and ECOG 0-1. Carbo-RT pts have more advanced disease: 52% stage IIIb-IVA vs 36.1% in cis-RT. At least one comorbidity was present in 41.8% in cis-RT and 84% in carbo-RT pts. Five or more chemo cycles were applied 87.3% in cis-RT and 84% pts in carbo-RT (p=0.749). PFS at 3 y was 24m in cis-RT (95% CI 18.8-29.3) vs 27.5m in carbo-RT (95% CI 25.6-29.4) (p=0.249). OS in 3y was 30.3m (95% CI 26.2-32.7) in cis-RT pts and 31.4m in carbo-RT (95% CI 29.9-32.9) (p=0.298). ORR (95.3% vs 95.4%) (p=0.911) and grade ≥ 3 toxicities (8.5% cis-RT vs 11.8% carbo-RT) (p=0.757) were similar. In multivariate analysis, only the ORR was a significance predictor of survival Conclusions: Patients with advanced CC treated with carbo-RT have no different 3 year OS, PFS ORR and toxicities when compared to cis-RT. Carbo-RT may be a treatment alternative in patients that could not receive cisplatin